Provided by Tiger Fintech (Singapore) Pte. Ltd.

Viking Therapeutics

33.40
+1.304.05%
Pre-market: 31.08-2.3200-6.95%06:11 EDT
Volume:5.90M
Turnover:197.66M
Market Cap:3.75B
PE:-28.96
High:34.40
Open:32.65
Low:32.16
Close:32.10
Loading ...

Why Viking Therapeutics, Inc. (VKTX) Went Up On Wednesday?

Insider Monkey
·
20 Feb

LLY Rises More Than 4% in a Week: How to Play the Stock

Zacks
·
13 Feb

Scotiabank Initiates Viking Therapeutics at Sector Outperform

MT Newswires Live
·
13 Feb

Viking Therapeutics Initiated at Sector Outperform by Scotiabank

Dow Jones
·
13 Feb

Why Viking Therapeutics Inc. (VKTX) Went Down on Monday

Insider Monkey
·
11 Feb

Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today

Motley Fool
·
11 Feb

The M&A Boom Of 2025 Is Just Getting Started - And Here Are 5 Potential Targets

Dow Jones
·
09 Feb

Viking Therapeutics price target lowered to $96 from $109 at B. Riley

TipRanks
·
08 Feb

Down 65%, Is Viking Therapeutics Stock a Buy on the Dip?

Motley Fool
·
08 Feb

Viking Therapeutics price target lowered to $95 from $120 at Truist

TIPRANKS
·
08 Feb

Truist Securities Adjusts Viking Therapeutics Price Target to $95 From $120, Maintains Buy Rating

MT Newswires Live
·
07 Feb

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

Dow Jones
·
07 Feb

U.S. RESEARCH ROUNDUP-Altus Power, Amazon, Nevro

Reuters
·
07 Feb

Viking Therapeutics Reports Strong Trials and Financial Health

TIPRANKS
·
07 Feb

Viking Therapeutics Is Maintained at Strong Buy by Raymond James

Dow Jones
·
07 Feb

Viking Therapeutics Reports Q4 2024 Financial Results, Advances VK2735 Trials

GuruFocus.com
·
07 Feb

Stock Track | Viking Therapeutics Plunges Nearly 10% on Q4 Earnings Miss, Lack of Major Obesity Drug Updates

Stock Track
·
06 Feb

Stock Track | Viking Therapeutics Plunges Nearly 10% on Q4 Miss, Lack of Major Pipeline Breakthroughs

Stock Track
·
06 Feb

Viking Therapeutics price target raised to $125 from $122 at Raymond James

TIPRANKS
·
06 Feb

VKTX's Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10%

Zacks
·
06 Feb